Ann: AusCann Investor Webinar, page-90

There will be no rerate on this stock until after phase 1 trial is done early next year. The stock price will continue to bounce around its current trading range until then - low 30's to low 40's. The fact it's down a few cents is meaningless in the scheme of things - its just usual stock market guesswork.

They've got plenty of money in the bank to fund all of next years activities - as mentioned in the interview.

For the longs everything is looking pretty good - still risks of course but that's stating the bleeding obvious.

It may even be a good time to stock up, there are plenty of recent examples of phase 1 trials generating a nice bump in a SP.

Ido made that capsule sound really sweet - (I can't remember the exact words he used) but I liked the bit where he said we should think about the capsule more as a cannabis delivery platform and not just a one-trick (pill) pony.

IMO